For decades, pancreatic cancer has been one of medicine's most stubborn opponents. Even with aggressive chemotherapy, five-year survival sits below 15%, and the protein that drives most cases — a mutated form of the cancer gene KRAS — has been famously labeled "undruggable." This week, that label finally cracked.
Results from a 500-patient trial of a once-daily pill called daraxonrasib show it nearly doubled how long people with advanced pancreatic cancer lived, lifting median survival from 6.7 months on standard chemotherapy to 13.2 months. The drug, developed by Revolution Medicines, also caused fewer harsh side effects than chemotherapy, opening up a new and more tolerable line of treatment for a disease that has barely budged in 50 years.
Hitting an "undruggable" target
Daraxonrasib belongs to a new class of medicines called RAS(ON) inhibitors. Instead of blocking KRAS only when it is in its "off" state, the pill latches onto the active, signal-firing form of the protein and shuts it down. That matters because more than 90% of pancreatic cancers depend on a mutated KRAS to keep growing — a vulnerability that scientists have spent more than 40 years trying to exploit.
By targeting multiple KRAS mutations at once rather than a single subtype, the drug widens the pool of patients who could benefit. Early data suggest it may also be effective in lung and colorectal cancers that share the same underlying biology.
"Really, really exciting"
Cancer specialists not involved in the trial called the results a turning point.
"Research has pretty much doubled survival rates across all cancers bar a few, but pancreatic cancer is one of those really stubborn cancers which has lagged behind," said Dr. Sam Godfrey of Cancer Research UK. "Anything which gives people more time when they have such an intractable, difficult-to-treat cancer is really, really exciting."
Regulators in the United States and Europe will now review the data to decide whether daraxonrasib can move toward standard-of-care use. Because pancreatic cancer trials so often produce disappointing results, oncologists say even a doubling of survival is the kind of headline they have been waiting a generation to see.
A pill, not a drip
For patients, the practical change could be just as meaningful as the science. Chemotherapy regimens for pancreatic cancer typically require repeated hospital infusions and bring grueling side effects — fatigue, nausea, neuropathy and weight loss that can erode quality of life. Daraxonrasib is taken at home as a daily pill, and the trial reported a milder side-effect profile, mostly low-grade rashes and digestive issues.
That matters because pancreatic cancer is often diagnosed late, when patients have little energy to spare. A treatment that buys more time and feels less brutal is, in this corner of oncology, a small revolution.
Part of a larger shift
The trial caps a remarkable run of progress against a disease long viewed as a dead end. In recent months, researchers have also reported an AI model that flags pancreatic cancer earlier from routine scans, and an mRNA vaccine that is showing promise after surgery. Together, the wave of advances suggests pancreatic cancer is finally catching up with the broader revolution in cancer care.
"This is not the end of the story for pancreatic cancer," one researcher told reporters, "but it is the first chapter in a long time that ends with the word 'progress.'"
